• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

雄激素受体共激活因子结合界面处的识别与适应性变化

Recognition and accommodation at the androgen receptor coactivator binding interface.

作者信息

Hur Eugene, Pfaff Samuel J, Payne E Sturgis, Grøn Hanne, Buehrer Benjamin M, Fletterick Robert J

机构信息

Graduate Group in Biophysics, University of California, San Francisco, California, USA.

出版信息

PLoS Biol. 2004 Sep;2(9):E274. doi: 10.1371/journal.pbio.0020274. Epub 2004 Aug 24.

DOI:10.1371/journal.pbio.0020274
PMID:15328534
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC509409/
Abstract

Prostate cancer is a leading killer of men in the industrialized world. Underlying this disease is the aberrant action of the androgen receptor (AR). AR is distinguished from other nuclear receptors in that after hormone binding, it preferentially responds to a specialized set of coactivators bearing aromatic-rich motifs, while responding poorly to coactivators bearing the leucine-rich "NR box" motifs favored by other nuclear receptors. Under normal conditions, interactions with these AR-specific coactivators through aromatic-rich motifs underlie targeted gene transcription. However, during prostate cancer, abnormal association with such coactivators, as well as with coactivators containing canonical leucine-rich motifs, promotes disease progression. To understand the paradox of this unusual selectivity, we have derived a complete set of peptide motifs that interact with AR using phage display. Binding affinities were measured for a selected set of these peptides and their interactions with AR determined by X-ray crystallography. Structures of AR in complex with FxxLF, LxxLL, FxxLW, WxxLF, WxxVW, FxxFF, and FxxYF motifs reveal a changing surface of the AR coactivator binding interface that permits accommodation of both AR-specific aromatic-rich motifs and canonical leucine-rich motifs. Induced fit provides perfect mating of the motifs representing the known family of AR coactivators and suggests a framework for the design of AR coactivator antagonists.

摘要

前列腺癌是工业化国家男性的主要杀手。这种疾病的根源是雄激素受体(AR)的异常作用。AR与其他核受体的区别在于,在激素结合后,它优先响应一组带有富含芳香族基序的特定共激活因子,而对其他核受体青睐的带有富含亮氨酸的“NR盒”基序的共激活因子反应较差。在正常情况下,通过富含芳香族基序与这些AR特异性共激活因子的相互作用是靶向基因转录的基础。然而,在前列腺癌期间,与这类共激活因子以及与含有典型富含亮氨酸基序的共激活因子的异常结合会促进疾病进展。为了理解这种异常选择性的矛盾之处,我们利用噬菌体展示技术获得了一组与AR相互作用的完整肽基序。对这些肽中的一组进行了结合亲和力测量,并通过X射线晶体学确定了它们与AR的相互作用。与FxxLF、LxxLL、FxxLW、WxxLF、WxxVW、FxxFF和FxxYF基序形成复合物的AR结构揭示了AR共激活因子结合界面不断变化的表面,该表面能够容纳AR特异性富含芳香族基序和典型富含亮氨酸基序。诱导契合为代表已知AR共激活因子家族的基序提供了完美匹配,并为AR共激活因子拮抗剂的设计提供了框架。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3e6/509409/b81a57959ca5/pbio.0020274.g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3e6/509409/4213ed3994ba/pbio.0020274.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3e6/509409/b98e1da835db/pbio.0020274.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3e6/509409/e425c79b8268/pbio.0020274.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3e6/509409/1636875aa28d/pbio.0020274.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3e6/509409/5ad4a4bdf1f4/pbio.0020274.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3e6/509409/7c7c689705aa/pbio.0020274.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3e6/509409/6e8d65d1e31c/pbio.0020274.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3e6/509409/a0b705bcca9a/pbio.0020274.g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3e6/509409/b81a57959ca5/pbio.0020274.g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3e6/509409/4213ed3994ba/pbio.0020274.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3e6/509409/b98e1da835db/pbio.0020274.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3e6/509409/e425c79b8268/pbio.0020274.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3e6/509409/1636875aa28d/pbio.0020274.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3e6/509409/5ad4a4bdf1f4/pbio.0020274.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3e6/509409/7c7c689705aa/pbio.0020274.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3e6/509409/6e8d65d1e31c/pbio.0020274.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3e6/509409/a0b705bcca9a/pbio.0020274.g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3e6/509409/b81a57959ca5/pbio.0020274.g009.jpg

相似文献

1
Recognition and accommodation at the androgen receptor coactivator binding interface.雄激素受体共激活因子结合界面处的识别与适应性变化
PLoS Biol. 2004 Sep;2(9):E274. doi: 10.1371/journal.pbio.0020274. Epub 2004 Aug 24.
2
The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor.雄激素受体在配体依赖性反式激活中辅助激活因子利用的分子机制。
J Biol Chem. 2005 Mar 4;280(9):8060-8. doi: 10.1074/jbc.M407046200. Epub 2004 Nov 24.
3
Androgen receptor ligand-binding domain interaction and nuclear receptor specificity of FXXLF and LXXLL motifs as determined by L/F swapping.通过亮氨酸/苯丙氨酸交换测定FXXLF和LXXLL基序的雄激素受体配体结合域相互作用及核受体特异性。
Mol Endocrinol. 2006 Aug;20(8):1742-55. doi: 10.1210/me.2005-0348. Epub 2006 Apr 20.
4
Expression and function of androgen receptor coactivators in prostate cancer.雄激素受体共激活因子在前列腺癌中的表达与功能
J Steroid Biochem Mol Biol. 2004 Nov;92(4):265-71. doi: 10.1016/j.jsbmb.2004.10.003. Epub 2004 Dec 19.
5
The use of phage display technique for the isolation of androgen receptor interacting peptides with (F/W)XXL(F/W) and FXXLY new signature motifs.利用噬菌体展示技术筛选具有(F/W)XXL(F/W)和FXXLY新特征基序的雄激素受体相互作用肽。
J Biol Chem. 2003 Jun 27;278(26):23691-8. doi: 10.1074/jbc.M211908200. Epub 2003 Apr 24.
6
Distinct recognition modes of FXXLF and LXXLL motifs by the androgen receptor.雄激素受体对FXXLF和LXXLL基序的不同识别模式。
Mol Endocrinol. 2004 Sep;18(9):2132-50. doi: 10.1210/me.2003-0375. Epub 2004 Jun 3.
7
Mechanisms of androgen receptor signalling via steroid receptor coactivator-1 in prostate.雄激素受体通过类固醇受体辅激活因子-1在前列腺中的信号传导机制。
Endocr Relat Cancer. 2004 Mar;11(1):117-30. doi: 10.1677/erc.0.0110117.
8
Selection of estrogen receptor beta- and thyroid hormone receptor beta-specific coactivator-mimetic peptides using recombinant peptide libraries.利用重组肽文库筛选雌激素受体β和甲状腺激素受体β特异性共激活剂模拟肽
Mol Endocrinol. 2000 May;14(5):605-22. doi: 10.1210/mend.14.5.0445.
9
Novel FXXFF and FXXMF motifs in androgen receptor cofactors mediate high affinity and specific interactions with the ligand-binding domain.雄激素受体辅助因子中的新型FXXFF和FXXMF基序介导与配体结合域的高亲和力和特异性相互作用。
J Biol Chem. 2006 Jul 14;281(28):19407-16. doi: 10.1074/jbc.M602567200. Epub 2006 May 11.
10
Identification of SRC3/AIB1 as a preferred coactivator for hormone-activated androgen receptor.鉴定 SRC3/AIB1 为激素激活的雄激素受体的首选共激活子。
J Biol Chem. 2010 Mar 19;285(12):9161-71. doi: 10.1074/jbc.M109.085779. Epub 2010 Jan 19.

引用本文的文献

1
A SARM a Day Keeps the Weakness Away: A Computational Approach for Selective Androgen Receptor Modulators (SARMs) and Their Interactions with Androgen Receptor and 5‑Alpha Reductase Proteins.每天一片选择性雄激素受体调节剂,远离虚弱:一种针对选择性雄激素受体调节剂(SARMs)及其与雄激素受体和5-α还原酶蛋白相互作用的计算方法。
ACS Omega. 2025 Jul 18;10(29):31649-31667. doi: 10.1021/acsomega.5c02504. eCollection 2025 Jul 29.
2
Hydroxychloroquine modulates the progression of experimentally induced benign prostatic hyperplasia in rats via targeting EGFR/ERK/STAT3 and AR/FOXO1/TRAIL pathways: computational and in vivo studies.羟氯喹啉通过靶向表皮生长因子受体/细胞外信号调节激酶/信号转导与转录激活因子3以及雄激素受体/叉头框蛋白O1/肿瘤坏死因子相关凋亡诱导配体通路调控大鼠实验性诱导的良性前列腺增生的进展:计算机模拟和体内研究
Sci Rep. 2025 Jun 20;15(1):20118. doi: 10.1038/s41598-025-04267-y.
3

本文引用的文献

1
Processing of X-ray diffraction data collected in oscillation mode.振荡模式下收集的X射线衍射数据的处理。
Methods Enzymol. 1997;276:307-26. doi: 10.1016/S0076-6879(97)76066-X.
2
Use of non-crystallographic symmetry in protein structure refinement.非晶体学对称性在蛋白质结构精修中的应用。
Acta Crystallogr D Biol Crystallogr. 1996 Jul 1;52(Pt 4):842-57. doi: 10.1107/S0907444995016477.
3
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.通过MDM2小分子拮抗剂在体内激活p53通路。
QSAR, molecular docking, MD simulations, and ADMET screening identify potential leads against key targets in benign prostatic hyperplasia.定量构效关系(QSAR)、分子对接、分子动力学(MD)模拟以及药物代谢动力学/药物毒性(ADMET)筛选确定了针对良性前列腺增生关键靶点的潜在先导化合物。
In Silico Pharmacol. 2024 Nov 19;12(2):107. doi: 10.1007/s40203-024-00280-7. eCollection 2024.
4
HIt Discovery using docking ENriched by GEnerative Modeling (HIDDEN GEM): A novel computational workflow for accelerated virtual screening of ultra-large chemical libraries.基于对接增强生成建模的 HIt 发现(HIDDEN GEM):一种用于加速超大规模化学库虚拟筛选的新型计算工作流程。
Mol Inform. 2024 Jan;43(1):e202300207. doi: 10.1002/minf.202300207. Epub 2023 Dec 19.
5
Streamlining Large Chemical Library Docking with Artificial Intelligence: the PyRMD2Dock Approach.用人工智能简化大型化学文库对接:PyRMD2Dock 方法。
J Chem Inf Model. 2024 Apr 8;64(7):2143-2149. doi: 10.1021/acs.jcim.3c00647. Epub 2023 Aug 8.
6
Characterization of allosteric modulators that disrupt androgen receptor co-activator protein-protein interactions to alter transactivation-Drug leads for metastatic castration resistant prostate cancer.鉴定破坏雄激素受体共激活蛋白-蛋白相互作用从而改变反式激活的变构调节剂-用于转移性去势抵抗性前列腺癌的药物先导物。
SLAS Discov. 2023 Oct;28(7):325-343. doi: 10.1016/j.slasd.2023.08.001. Epub 2023 Aug 6.
7
UBR5 forms ligand-dependent complexes on chromatin to regulate nuclear hormone receptor stability.UBR5 在染色质上形成配体依赖性复合物,以调节核激素受体的稳定性。
Mol Cell. 2023 Aug 3;83(15):2753-2767.e10. doi: 10.1016/j.molcel.2023.06.028. Epub 2023 Jul 20.
8
A partially open conformation of an androgen receptor ligand-binding domain with drug-resistance mutations.雄激素受体配体结合域的部分开放构象与耐药突变。
Acta Crystallogr F Struct Biol Commun. 2023 Apr 1;79(Pt 4):95-104. doi: 10.1107/S2053230X23002224. Epub 2023 Mar 30.
9
Dynamic phase separation of the androgen receptor and its coactivators key to regulate gene expression.雄激素受体及其共激活因子的动态相分离是调节基因表达的关键。
Nucleic Acids Res. 2023 Jan 11;51(1):99-116. doi: 10.1093/nar/gkac1158.
10
A structural mechanism of nuclear receptor biased agonism.核受体偏倚激动剂的结构机制。
Proc Natl Acad Sci U S A. 2022 Dec 13;119(50):e2215333119. doi: 10.1073/pnas.2215333119. Epub 2022 Dec 5.
Science. 2004 Feb 6;303(5659):844-8. doi: 10.1126/science.1092472. Epub 2004 Jan 2.
4
Recent advances in androgen receptor action.雄激素受体作用的最新进展。
Cell Mol Life Sci. 2003 Aug;60(8):1613-22. doi: 10.1007/s00018-003-2309-3.
5
Novel selective inhibitors of the interaction of individual nuclear hormone receptors with a mutually shared steroid receptor coactivator 2.新型选择性抑制剂,可抑制单个核激素受体与共同共享的类固醇受体辅激活因子2之间的相互作用。
J Am Chem Soc. 2003 Jun 11;125(23):6852-3. doi: 10.1021/ja0348391.
6
The use of phage display technique for the isolation of androgen receptor interacting peptides with (F/W)XXL(F/W) and FXXLY new signature motifs.利用噬菌体展示技术筛选具有(F/W)XXL(F/W)和FXXLY新特征基序的雄激素受体相互作用肽。
J Biol Chem. 2003 Jun 27;278(26):23691-8. doi: 10.1074/jbc.M211908200. Epub 2003 Apr 24.
7
A gene-expression inhibitor that targets an alpha-helix-mediated protein interaction.一种靶向α-螺旋介导的蛋白质相互作用的基因表达抑制剂。
J Am Chem Soc. 2003 Apr 30;125(17):4992-3. doi: 10.1021/ja0292703.
8
Electrostatic modulation in steroid receptor recruitment of LXXLL and FXXLF motifs.类固醇受体招募LXXLL和FXXLF基序中的静电调制。
Mol Cell Biol. 2003 Mar;23(6):2135-50. doi: 10.1128/MCB.23.6.2135-2150.2003.
9
Androgen receptors in prostate cancer.前列腺癌中的雄激素受体
Endocr Relat Cancer. 2002 Sep;9(3):155-70. doi: 10.1677/erc.0.0090155.
10
Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition.糖皮质激素受体配体结合域的晶体结构揭示了受体二聚化和共激活因子识别的新模式。
Cell. 2002 Jul 12;110(1):93-105. doi: 10.1016/s0092-8674(02)00817-6.